Ludiflash® is a combined filler, binder and disintegrant, designed to dissolve in the mouth within seconds.
Ludiflash® is a combined filler, binder and disintegrant, designed to dissolve in the mouth within seconds.
Ludiflash® comprises the following ingredients: 90 percent Mannitol, a fast-dissolving filler with a mildly sweet taste; 5 percent Kollidon® CL-SF (crospovidone), a superior tablet disintegrant that is effective even with very little liquid; and 5 percent Kollicoat® SR 30 D (polyvinyl acetate), a hydrophobic binder. Each component complies with all leading pharmacopoeia monographs. Plus, the fast-disintegrating, fast-acting formulations created with Ludiflash® offer an exceptionally smooth and creamy mouthfeel – enhancing patient compliance.
Ludiflash® delivers tangible benefits to manufacturers, exhibiting good flowability, compressibility and stability. The compound’s low hygroscopicity ensures the stability of the active ingredient and of the tablet itself.
Ludiflash® is suitable for direct compression and roller compaction, and can be deployed in wet-granulation processes. Blends can be processed on standard tableting machines or used in the form of granulate or powder. When a standard tableting process is used, Ludiflash® ensures excellent uniformity, even at high speeds: creating compact and highly porous tablets that offer exceptional hardness and low friability, making them suitable for polyethylene containers and push-through blisters.
www.pharma-ingredients.basf.com/Ludiflash/Home.aspx
pharma-ingredients@basf.com
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.